Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BV100 Multiple Ascending Dose Study in Healthy Males
NCT05087069Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Acinetobacter baumannii infection comparing BV100 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) at 21 Days. Started Oct 2021; status: completed.
02
Drugs
BV100
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT05087069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087069.